Displaying drugs 1 - 25 of 12616 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| HPA-23 | 6685.04 H68N17Na2O86Sb9W21 |  | HPA-23 is an investigational antiviral compound. | Antineoplastic Agents / Antiviral Agents |
| Lumefantrine co-artemether | 6116.74 C346H378Cl33N11O16 |  | Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether... | Not Annotated |
| Tetracycline phosphate complex | 4821.729 C198H225N18NaO102P10 |  | Not Annotated | Anti-Bacterial Agents |
| Imetelstat | 4610.18 C148H211N68O53P13S13 |  | Imetelstat is under investigation in clinical trial NCT01916187 (Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma). | Enzyme Inhibitors / Telomerase, antagonists & inhibitors |
| Obinepitide | 4212.78 C185H288N54O55S2 |  | Investigated for use/treatment in obesity. | Not Available |
| Semaglutide | 4113.641 C187H291N45O59 |  | A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults. | Glucagon-like peptide-1 (GLP-1) analogues |
| Pramlintide | 3949.44 C171H267N51O53S2 |  | An amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. | Amylin Analog |
| D-JNKI-1 | 3823.498 C164H285N65O41 |  | Investigated for use/treatment in hearing loss. | Neuroprotective Agents |
| Brimapitide | 3822.514 C164H286N66O40 |  | Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers). | Neuroprotective Agents |
| Cotadutide | 3728.092 C167H252N42O55 |  | Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes). | Amino Acids, Peptides, and Proteins |
| Zilucoplan | 3562.229 C172H278N24O55 |  | A complement inhibitor used to treat generalized myasthenia gravis in anti-acetylcholine receptor (AChR) antibody-positive adults. | Amino Acids, Peptides, and Proteins / Blood Proteins / Complement Inactivating Agents / Immunoproteins / Peptides / Proteins |
| Ularitide | 3505.926 C145H234N52O44S3 |  | Investigated for use/treatment in congestive heart failure. | Bronchodilator Agents / Diuretics |
| Calmangafodipir | 3397.468 C110H150Ca4MnN20O70P10 |  | Not Annotated | Contrast Media |
| Avexitide | 3369.8 C149H234N40O47S |  | Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia). | Glucagon-Like Peptide 1 |
| Elcatonin | 3363.827 C148H244N42O47 |  | Not Annotated | Calcitonin Preparations |
| Taspoglutide | 3339.763 C152H232N40O45 |  | Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... | GLP-1 Agonists |
| Vasoactive intestinal peptide | 3326.83 C147H237N43O43S |  | Not Annotated | Gastrointestinal Agents / Neuroprotective Agents / Vasodilating Agents |
| Aviptadil | 3255.75 C145H232N40O43S |  | Not Annotated | Erectile Dysfunction |
| C-peptide | 3020.304 C129H211N35O48 |  | C-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy). | Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Insulin / Pancreatic Hormones / Peptide Hormones / Peptides |
| Tetracosactide | 2933.49 C136H210N40O31S |  | A diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency. | Adrenocorticotropic Hormone / Hormones |
| Delcasertib | 2880.31 C120H199N45O34S2 |  | Investigated for use/treatment in myocardial infarction. | Protein Kinase C-delta, antagonists & inhibitors |
| EP-217609 | 2647.75 C95H151N11O59S8 |  | Not Annotated | Carbohydrates / Coenzymes / Enzymes and Coenzymes / Imidazoles / Polysaccharides |
| Ziconotide | 2639.14 C102H172N36O32S7 |  | An N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics. | Analgesics |
| Ramoplanin | 2554.066 C119H154ClN21O40 |  | For the treatment of bacterial infections. | Anti-Bacterial Agents |
| Pexiganan | 2477.224 C122H210N32O22 |  | Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers). | Anti-Bacterial Agents |
Displaying drugs 1 - 25 of 12616 in total